{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:54:08Z","timestamp":1786982048654,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009964","name":"Tangshan Science and Technology Bureau","doi-asserted-by":"publisher","award":["B202302016"],"award-info":[{"award-number":["B202302016"]}],"id":[{"id":"10.13039\/501100009964","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11739-026-04326-w","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:17:25Z","timestamp":1774984645000},"page":"1343-1353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials"],"prefix":"10.1007","volume":"21","author":[{"given":"Shuai","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaochen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhe","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4182-7244","authenticated-orcid":false,"given":"Xiangming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"2","key":"4326_CR1","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song SJ, Lai JC, Wong GL, Wong VW, Yip TC (2024) Can we use old NAFLD data under the new MASLD definition? J Hepatol 80(2):e54\u2013e56","journal-title":"J Hepatol"},{"issue":"5","key":"4326_CR2","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhou F, Wang W et al (2020) Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology 71(5):1851\u20131864","journal-title":"Hepatology"},{"issue":"3","key":"4326_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM (2019) Non-alcoholic fatty liver disease\u2014a global public health perspective. J Hepatol 70(3):531\u2013544","journal-title":"J Hepatol"},{"issue":"9","key":"4326_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7(9):851\u2013861","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"4326_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD (2021) Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 6(7):578\u2013588","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"4326_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V et al (2024) EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81(3):492\u2013542","journal-title":"J Hepatol"},{"issue":"5","key":"4326_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797\u20131835","journal-title":"Hepatology"},{"key":"4326_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4747","volume":"372","author":"ML Petroni","year":"2021","unstructured":"Petroni ML, Brodosi L, Bugianesi E, Marchesini G (2021) Management of non-alcoholic fatty liver disease. BMJ 372:m4747","journal-title":"BMJ"},{"issue":"10402","key":"4326_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM et al (2023) Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402(10402):613\u2013626","journal-title":"Lancet"},{"issue":"6","key":"4326_CR10","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jhep.2025.03.003","volume":"82","author":"S Sabatini","year":"2025","unstructured":"Sabatini S, Gastaldelli A (2025) Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor. J Hepatol 82(6):950\u2013952","journal-title":"J Hepatol"},{"key":"4326_CR11","unstructured":"Administration USFaD (2024) FDA approves first treatment for patients with liver scarring due to fatty liver disease. U.S. Food and Drug Administration. Accessed Published 14 Mar 2024"},{"key":"4326_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"4326_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"4326_CR14","unstructured":"Higgins JPT TJ, Chandler J, et al (eds) (2023) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane. Published 2023"},{"issue":"6","key":"4326_CR15","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Sanyal AJ, Loomba R et al (2020) Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43(6):1352\u20131355","journal-title":"Diabetes Care"},{"issue":"1","key":"4326_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/apt.18042","volume":"60","author":"R Vuppalanchi","year":"2024","unstructured":"Vuppalanchi R, Loomba R, Sanyal AJ et al (2024) Randomised clinical trial: design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures. Aliment Pharmacol Ther 60(1):17\u201332","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"4326_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ et al (2024) Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 391(4):299\u2013310","journal-title":"N Engl J Med"},{"key":"4326_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106170","volume":"98","author":"MF Sven","year":"2020","unstructured":"Sven MF, Pierre B, Manal FA et al (2020) A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study. Contemp Clin Trials 98:106170","journal-title":"Contemp Clin Trials"},{"issue":"17","key":"4326_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V et al (2021) A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med 385(17):1547\u20131558","journal-title":"N Engl J Med"},{"issue":"1","key":"4326_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/apt.17734","volume":"59","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Ratziu V, Anstee QM et al (2024) Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 59(1):51\u201363","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"4326_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/hep4.1657","volume":"5","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Bashir M, Moussa SE et al (2021) Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol Commun 5(4):573\u2013588","journal-title":"Hepatol Commun"},{"issue":"4","key":"4326_CR22","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1097\/HEP.0000000000001084","volume":"81","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Stepanova M, Racila A et al (2025) Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology 81(4):1318\u20131327","journal-title":"Hepatology"},{"issue":"6","key":"4326_CR23","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA (2022) Hepatic fat reduction due to Resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life. Clin Gastroenterol Hepatol 20(6):1354-1361.e1357","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"4326_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390(6):497\u2013509","journal-title":"N Engl J Med"},{"issue":"10213","key":"4326_CR25","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD et al (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394(10213):2012\u20132024","journal-title":"Lancet"},{"issue":"11","key":"4326_CR26","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW et al (2023) Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 29(11):2919\u20132928","journal-title":"Nat Med"},{"issue":"12","key":"4326_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384(12):1113\u20131124","journal-title":"N Engl J Med"},{"issue":"6","key":"4326_CR28","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","volume":"82","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R (2025) Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis. Hepatology 82(6):1523\u20131533","journal-title":"Hepatology"},{"issue":"17","key":"4326_CR29","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J et al (2021) Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 385(17):1559\u20131569","journal-title":"N Engl J Med"},{"key":"4326_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186425","author":"PN Newsome","year":"2025","unstructured":"Newsome PN, Loomba R (2025) Therapeutic horizons in metabolic dysfunction-associated steatohepatitis. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI186425","journal-title":"J Clin Invest"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04326-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:07:05Z","timestamp":1781262425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04326-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4326"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04326-w","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}